AprilBio Co.,Ltd. (397030.KQ) Stock

397030.KQ logo

AprilBio Co.,Ltd.

397030.KQSouth Korea
Healthcare

Company profile

AprilBio reported revenue of 2.17 billion KRW for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 725.35 million KRW. In Q1 2026 it reported net income of 200.99 million KRW, against net income of 593.65 million KRW a year earlier.

What stands out

  • Revenue fell 92.1% in fiscal year 2025, from 27.51 billion KRW in fiscal year 2024.
  • It reported a net loss of 9.73 billion KRW in fiscal year 2025, after a profit of 20.01 billion KRW in fiscal year 2024.
  • The fall in revenue eased in Q1 2026: down 66.6% from a year before.
  • It spent 4.02 billion KRW on research and development in fiscal year 2025, more than its revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

About AprilBio Co.,Ltd.

AprilBio Co.,Ltd. develops long-acting type biobetter and antibody biologics. The company develops antibody drugs, double antibodies, long-acting antibody drugs, long-acting protein drugs, and ADC-applied antibodies. It is developing various products for use in the treatment of rare diseases, cancer, male infertility, autoimmune and inflammatory diseases. The company was founded in 2013 and is headquartered in Chuncheon-si, South Korea.

Largest shareholders

  • IMM Investment Corp.21.71%
  • Tkg Huchems Co., Ltd.12.67%
  • Sang-Hun Cha9.634 %9.63%
  • SM-Sino Technology Investment Co. Ltd.3.95%
  • Jin-Taek Kim0.3338 %0.33%

Share of the company, as of September 25, 2026

Leadership

  • Sang-Hoon Cha — Chief Executive Officer
  • Jin-Taek Kim — CFO, Head of Business Management Division & Director of Administration Division
  • Moo Yong Song — CTO & Head of Research & Planning Division and Member of BD Advisory Board
  • Seung Goo Kang — CSO
  • Jae Heung Lee — CDO and Director of R&D Division

How much revenue does AprilBio make?

AprilBio reported 2.17 billion KRW in revenue for fiscal year 2025, down 92.1% from 27.51 billion KRW in fiscal year 2024. In Q1 2026 revenue was 725.35 million KRW.

What companies are similar to AprilBio?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Bukwang Pharmaceutical Co., Ltd. (003000.KS), Ildong Pharmaceutical Co., Ltd. (249420.KS), Dong-A ST Co., Ltd. (170900.KS), HLB Pharmaceutical Co., Ltd. (047920.KQ).

How much does AprilBio spend on research and development?

Research and development by fiscal year: FY2021, 13.89 billion KRW; FY2022, 6.92 billion KRW; FY2023, 8.04 billion KRW; FY2024, 3.20 billion KRW; FY2025, 4.02 billion KRW.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Founded2013
IPO DateJul 28, 2022
IPO StatusPublic
HeadquartersChuncheon-si, South Korea
ExchangeKOSDAQ
TimezoneAsia/Seoul (KST)

Contact & Links

Address
Room 602, Building B, Chuncheon-si, 24341
Phone
82 2 6956 8383
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “AprilBio Co.,Ltd. (397030.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/397030.KQ

LinkedInLinkedInXXYouTubeYouTube